Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome
Background: Leiomyomata causing symptoms have a deleterious effect on the health of women during reproductive age. Mifepristone, a progesterone antagonist was studied for reduction of symptoms in leiomyomata in perimenopausal women. Material and Methods: Mifepristone was adminstered to 7 women aged...
Main Author: | Deepti Jain |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Journal of Mid-Life Health |
Subjects: | |
Online Access: | http://www.jmidlifehealth.org/article.asp?issn=0976-7800;year=2018;volume=9;issue=2;spage=65;epage=71;aulast=Jain |
Similar Items
-
Mifepristone and Misoprostol Induced Abortion with A Large Myomatous Uterus
by: Yiu-Tai Li, et al.
Published: (2005-06-01) -
A prospective interventional study to evaluate the effects of medical therapy (Mifepristone 25 mg) on the management of uterine fibroids
by: Meeta Gupta, et al.
Published: (2020-01-01) -
Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas
by: Shen Q, et al.
Published: (2019-09-01) -
Antitumor effect of mifepristone on human endometrial stromal cell line
by: Luković Jovan, et al.
Published: (2021-01-01) -
The Promise of Mifepristone: Perspectives and Experiences Across Canada
by: Vogel, Kristina I.
Published: (2016)